Jorge Cortes, MD / Elias Jabbour, MD - Care Strategies for Chronic Myeloid Leukemia in Chronic Phase: Customizing Frontline TKI Therapy to Optimize Long-term Patient Outcomes

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 9AM EDT 5 min · 24 Sep 2026 · NPR News Now

9AM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

The Critic Who Finally Came Around | Jeanine Pt. 5 6 min · 24 Sep 2026 · The Best 5 Minute Wine Podcast

Ambitious But Lazy? Use This CIA Trick to Beat 99% of People 19 min · 24 Sep 2026 · EverydaySpy Podcast

Postpartum Fitness & My Boob Job… 1h 15m · 24 Sep 2026 · Pursuit of Wellness

326. Rethinks: The Secrets to Getting the Information You Need from AI 28 min · 24 Sep 2026 · Think Fast Talk Smart: Communication Techniques

Report any issue

Source

Recorded08 Jan 2025

Publisherc.answersincme.com ↗

Handlerec:766003

Show notes

Please visit answersincme.com/MNK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss strategies for the use of novel tyrosine kinase inhibitors (TKIs) in the management of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using novel TKIs for newly diagnosed CP-CML; Discuss the clinical implications of the latest data for first-line novel TKIs in CP-CML; and Outline potential considerations to optimize outcomes for newly diagnosed patients with CP-CML on first-line TKIs.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in